Ip EH, Saldana S, Miller KD, Carlos RC, et al. Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events. Cancer 2021 Nov 2. doi: 10.1002/cncr.33992.
PMID: 34726788